Comparative bioequivalence study of Pioglitazone tablets, 20 mg (JSC «Chimpharm», Kazakhstan) and Actos® Tablets, 30 mg («Eli Lilly Holdings, Takeda Global Research and Development Centre Europe Ltd»)

Comparative bioequivalence study of Pioglitazone tablets, 20 mg (JSC «Chimpharm», Kazakhstan) and Actos® Tablets, 30 mg («Eli Lilly Holdings, Takeda Global Research and Development Centre Europe Ltd»)

Within the cross, a single, open, randomized study with a two-week washout period, the two sequences has been studied bioequivalence of tablet forms two pioglitazone 18 volunteers (30 mg dosage). Plasma samples were analyzed by a validated HPLC-MS/MS within 48 hours. Analyzed for drugs following pha...

Full description

Saved in:
Bibliographic Details
Main Authors: A. K. Sariev (Author), D. A. Abaimov (Author), M. V. Shiryaev (Author), E. Y. Styrova (Author), S. A. Altynbekov (Author), G. A. Dzholdygulov (Author), V. N. Seryakov (Author), Y. M. Budach (Author), O. E. Kurilo (Author)
Format: Book
Published: LLC "Publisher OKI", 2013-09-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items